Skip to main content
Clinical Trials/NL-OMON32275
NL-OMON32275
Completed
Phase 4

A phase IV prospective, multicentre, randomized, open-label trial to assess the efficacy and safety of GONAL f® at a dose based on subject baseline characteristics determined according to the CONSORT calculator compared with a standard dose of GONAL f® 150 IU per day for ovarian stimulation in women undergoing assisted reproductive technology (ART) - CONSORT RCT in ART

Serono0 sites20 target enrollmentTBD

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
infertility
Sponsor
Serono
Enrollment
20
Status
Completed
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Interventional

Investigators

Sponsor
Serono

Eligibility Criteria

Inclusion Criteria

  • Be a female subject justifying an IVF/ET treatment,
  • Be between her 18th and 35th birthday (35 not included) at the time of the randomisation visit,
  • A body mass index (BMI) \< 30 kg/m2 where the BMI is calculated
  • Have early follicular phase (day 2\-4\) serum level of basal FSH £ 12 IU/L measured in the centre\*s local laboratory during the screening period (i.e. within 2 months prior to down regulation start),

Exclusion Criteria

  • Had \>\= 2 previous ART cycles with a poor response to gonadotrophin stimulation (defined as \< 5 mature follicles and/or \< 3 oocytes collected) or had \>\= 2 previous ART cycles with a hyper response (defined as ³ 25 oocytes retrieved),

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, Not Recruiting
Phase 1
A phase IV prospective, multicentre, randomized, open-label trial to assess the efficacy and safety of GONAL f® at a dose based on subject baseline characteristics determined according to the CONSORT calculator compared with a standard dose of GONAL f® 150 IU per day for ovarian stimulation in women undergoing assisted reproductive technology (ART) - CONSORT RCT in ART
EUCTR2008-001259-22-FRMerck Serono International S.A.
Active, Not Recruiting
N/A
A phase IV prospective, multicentre, randomized, open-label trial to assess the efficacy and safety of GONAL f® at a dose based on subject baseline characteristics determined according to the CONSORT calculator compared with a standard dose of GONAL f® 150 IU per day for ovarian stimulation in women undergoing assisted reproductive technology (ART) - CONSORT RCT in ARTOvarian stimulation in women undergoing assisted reproductive technologyMedDRA version: 9.1Level: LLTClassification code 10021930Term: Infertility NOS
EUCTR2008-001259-22-DEMerck Serono S.A.200
Active, Not Recruiting
N/A
A phase IV prospective, multicentre, randomized, open-label, trial to assess the efficacy and safety of GONAL-f at a dose based on subject baseline characteristics determined according to the CONSORT calculator compared with a standard dose of GONAL-f 150 IU per day for ovarian stimulation in women undergoing assisted reproductive technology (ART) - CONSORT RCT in ARTOvarian stimulation in women undergoing assisted reproductive technologyMedDRA version: 9.1Level: LLTClassification code 10021930Term: Infertility NOS
EUCTR2008-001259-22-ITMERCK SERONO INTERNATIONAL SA200
Active, Not Recruiting
N/A
A phase IV prospective, multicentre, randomized, open-label trial to assess the efficacy and safety of GONAL f® at a dose based on subject baseline characteristics determined according to the CONSORT calculator compared with a standard dose of GONAL f® 150 IU per day for ovarian stimulation in women undergoing assisted reproductive technology (ART) - CONSORT RCT in ARTOvarian stimulation in women undergoing assisted reproductive technologyMedDRA version: 9.1Level: LLTClassification code 10021930Term: Infertility NOS
EUCTR2008-001259-22-NLMerck Serono International S.A.200
Active, Not Recruiting
N/A
A phase IV prospective, multicentre, randomized, open-label trial to assess the efficacy and safety of GONAL f® at a dose based on subject baseline characteristics determined according to the CONSORT calculator compared with a standard dose of GONAL f® 150 IU per day for ovarian stimulation in women undergoing assisted reproductive technology (ART) - CONSORT RCT in ARTOvarian stimulation in women undergoing assisted reproductive technologyMedDRA version: 9.1Level: LLTClassification code 10021930Term: Infertility NOS
EUCTR2008-001259-22-GBMerck Serono S.A. Geneva200